Oncocyte 

$3.17
0
+$0.13+4.35% Wednesday 14:21

Statistik

Harga Tertinggi Hari
3.17
Harga Terendah Hari
3.17
52M Tertinggi
4.23
52M Terendah
0.21
Volum
10
Volum Purata
382
Kapasiti Pasaran
26.59B
Nisbah P/E
-
Pendapatan Dividen
-
Dividen
-

Akan Datang

Pendapatan

7NovDijangka
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Seterusnya
-1.01
-0.7
-0.39
-0.08
EPS yang dijangka
-0.436667
EPS sebenar
N/A

Orang Lain Juga Mengikuti

Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti 0KCC.LSE. Ini bukan cadangan pelaburan.

Peserta

Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.

Mengenai

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Show more...
CEO
Mr. Joshua Riggs
Pekerja
43
Negara
US
ISIN
US68235C2061

Penyenaraian